Trans-Resveratrol

Trans-resveratrol is a plant polyphenol best known for activating SIRT1, a longevity-linked enzyme central to NAD+-dependent cellular signaling. Clinical research supports its benefits for cardiovascular health and inflammation, with promising evidence for metabolic health and cognitive protection. This guide covers the mechanisms, evidence, dosing, and safety in depth.

Quick Facts

• Category: Polyphenol, phytonutrient, stilbene compound
• Also known as: 3,5,4'-trihydroxy-trans-stilbene, trans-3,4',5-trihydroxystilbene
• Most-studied form: Trans-resveratrol (crystalline powder in capsule)
• Key benefit: SIRT1 activation and NAD+-dependent longevity signaling
• Bioavailability: Moderate, roughly 20-40% oral bioavailability, significantly enhanced by piperine co-administration
• Found in: Red grapes (skin), red wine, Japanese knotweed, peanuts, berries, dark chocolate

What Is Trans-Resveratrol?

Trans-resveratrol is a naturally occurring polyphenolic stilbene, a plant compound belonging to the broader class of phytonutrients called phenolics. It exists in two geometric isomers, trans (straight-chain configuration) and cis (bent configuration), with trans being the biologically active form. The compound was first isolated in 1940 from hellebore root, but its health-promoting potential wasn't recognized until the 1990s following the French Paradox research, which examined the heart-protective effects of red wine consumption despite high saturated fat intake.

Resveratrol is classified as a non-essential nutrient, meaning the body does not require it for basic survival, yet emerging evidence suggests it confers protective and longevity-related benefits. It is a secondary metabolite produced by plants in response to stress, particularly UV exposure and fungal infection, acting as a natural antimicrobial and antioxidant defense system.

Natural Food Sources and Approximate Content

• Red wine: 0.5 to 5 mg per glass (content varies by vintage and region)
• Red grape skin: 50 to 100 mcg per gram
• Japanese knotweed root: 0.5 to 1.9 mg per gram, one of the richest natural sources
• Raw peanuts: 0.3 to 0.7 mcg per gram
• Dark chocolate (70% cacao or higher): 1.6 to 12 mg per 100g
• Mulberries and blueberries: trace amounts

Clinical trial doses of 250 to 500mg would require consuming dozens of glasses of red wine daily or hundreds of grams of Japanese knotweed root, highlighting why resveratrol is best understood as a supplement rather than something reliably obtained through whole foods in therapeutic quantities.

Forms & Bioavailability

Why Trans-Resveratrol Is the Active Form

The geometric structure of trans-resveratrol allows proper spatial alignment with SIRT1 enzyme binding pockets, enabling allosteric activation. The cis form has different three-dimensional geometry due to steric hindrance, preventing effective SIRT1 interaction. Additionally, cis-resveratrol is inherently unstable and spontaneously isomerizes to trans under exposure to light, heat, or UV radiation, which is why natural sources predominantly contain the trans form.

The Bioavailability Challenge

Trans-resveratrol's primary limitation is bioavailability: rapid hepatic metabolism via glucuronidation and sulfation reduces systemic exposure significantly. Piperine, a phytochemical from black pepper extract, addresses this by inhibiting UDP-glucuronosyltransferase (UGT) and sulfotransferase (SULT) enzymes in the liver and intestines, the very pathways that deactivate resveratrol. Research demonstrates that piperine co-administration (typically 5 to 20mg) can increase trans-resveratrol bioavailability by 40 to 70%, dramatically enhancing systemic exposure and SIRT1 activation efficiency.

Mechanisms of Action

SIRT1 Activation (Central Mechanism)

SIRT1 is a NAD+-dependent histone deacetylase and a master regulator of cellular stress responses and longevity. Resveratrol acts as an allosteric activator of SIRT1, enhancing its enzymatic activity even at moderate intracellular NAD+ concentrations. This activation triggers a cascade of downstream effects, including deacetylation of PGC-1 alpha, a co-activator of mitochondrial biogenesis and oxidative metabolism, deacetylation of p53, modulating apoptosis and DNA repair pathways, and enhanced mitochondrial function and ATP production.

A key mechanistic relationship in longevity research involves NAD+ precursor compounds, which raise cellular NAD+ pools, while resveratrol amplifies SIRT1's response to that increased NAD+ availability. A NAD+ precursor without an SIRT1 activator provides substrate without amplification; resveratrol without adequate NAD+ lacks the cofactor for full activity. Together they represent complementary mechanisms for sirtuin-driven cellular signaling that are frequently studied in combination in longevity research.

AMPK Pathway Activation

Resveratrol stimulates AMP-activated protein kinase (AMPK), a cellular energy sensor. AMPK activation mimics exercise and caloric restriction, increasing mitochondrial biogenesis, enhancing glucose uptake and insulin sensitivity, shifting metabolism toward fat oxidation, and activating autophagy.

NF-kB Inhibition (Anti-Inflammatory)

Resveratrol suppresses nuclear factor kappa B (NF-kB), a master transcription factor driving inflammatory gene expression. By blocking NF-kB, resveratrol reduces production of pro-inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) and adhesion molecules, lowering chronic low-grade inflammation.

Mitochondrial Biogenesis via PGC-1 Alpha

Through SIRT1 activation, resveratrol enhances PGC-1 alpha signaling, triggering the expression of mitochondrial genes and the biogenesis of new mitochondria. This is particularly relevant in aging, where mitochondrial content and function decline.

Antioxidant Activity via Nrf2

Resveratrol activates Nrf2 (nuclear factor erythroid 2-related factor 2), which binds to antioxidant response elements in promoter regions of antioxidant genes. This upregulates production of endogenous antioxidants like superoxide dismutase, catalase, and glutathione peroxidase, providing sustained cellular defense rather than direct free radical scavenging alone.

Evidence-Based Benefits

Cardiovascular health. Evidence level: Established in animal models; supported by multiple human RCTs. Resveratrol has demonstrated benefits for cardiovascular function in multiple human randomized controlled trials, including improved endothelial-dependent vasodilation, reduced arterial stiffness, reduced markers of systemic inflammation (CRP, IL-6), and modest reductions in blood pressure in some trials. Some recent trials have failed to show effects on traditional cardiovascular risk markers like cholesterol at certain doses, suggesting individual response variability and the need for dose optimization.

Anti-inflammatory effects. Evidence level: Established. Resveratrol consistently suppresses inflammatory markers across diverse populations, reducing TNF-alpha, IL-6, and IL-1beta production, lowering CRP, inhibiting NF-kB nuclear translocation, and decreasing inflammatory lipid mediators. These effects have been demonstrated in metabolic syndrome, type 2 diabetes, and obesity populations, and the anti-inflammatory benefit is among the most robustly established effects in human studies.

Sirtuin activation and longevity signaling. Evidence level: Promising. Direct evidence of SIRT1 activation in humans is limited, since SIRT1 activity is best measured in cell and animal models, but indirect markers support pathway engagement, including improved mitochondrial function and biogenesis markers, enhanced NAD+ metabolism, and increased expression of SIRT1-dependent genes. Long-term human lifespan studies with resveratrol are not feasible, so evidence relies on mechanistic studies, biomarker shifts, and observational data.

Cognitive health and neuroprotection. Evidence level: Promising. Resveratrol crosses the blood-brain barrier and exerts multiple neuroprotective effects, including inhibiting amyloid-beta aggregation, modulating tau protein phosphorylation, reducing neuroinflammation via NF-kB inhibition, enhancing mitochondrial function in neurons, and promoting autophagy. The Resveratrol in Alzheimer Disease (RAVE) and other randomized controlled trials show potential for slowing cognitive decline in early Alzheimer's disease, with preliminary data suggesting resveratrol may delay progression by 25 to 30% versus placebo over 12 to 52 weeks, though more robust trials are underway. Extensive preclinical studies demonstrate resveratrol reduces amyloid burden, improves memory, and preserves synaptic plasticity in transgenic Alzheimer's models.

Metabolic health and insulin sensitivity. Evidence level: Promising. Multiple trials show metabolic benefits, particularly in overweight and metabolically compromised individuals, including improved insulin sensitivity (HOMA-IR reduction), modest improvements in fasting glucose, enhanced mitochondrial function, and favorable changes in lipid profiles in some populations. Effects are most pronounced in individuals with baseline metabolic impairment, and dose and duration matter, with longer-term studies (12+ weeks) showing greater benefits than short interventions.

Athletic recovery and exercise performance. Evidence level: Emerging. Resveratrol activates similar pathways to exercise (SIRT1, AMPK, PGC-1 alpha), potentially amplifying training adaptations. However, human evidence is mixed: some small trials show enhanced endurance performance markers when combined with exercise training, while others show minimal additive effects beyond exercise alone. A theoretical concern that resveratrol's antioxidant activity might blunt adaptive oxidative stress responses from training has been raised but not definitively demonstrated in humans.

Skin health and photoprotection. Evidence level: Emerging. Resveratrol has demonstrated photoprotective and anti-aging effects in cell and animal models, including reducing UV-induced oxidative stress and DNA damage, inhibiting inflammatory mediators in skin, enhancing skin barrier function, and potentially reducing collagen degradation. However, human trial data is limited, and the systemic benefits for skin health (via cardiovascular and mitochondrial improvements) are more established than direct topical skin benefits.

Dosage & Timing

Dose-response studies show meaningful SIRT1 pathway engagement at 250 to 400mg, with diminishing returns above 500mg in most populations. Doses above 1000mg have been used safely in trials but with increased GI symptoms.

Timing and Administration

Resveratrol is fat-soluble (lipophilic), and absorption is significantly enhanced when consumed with dietary fat. Meals containing 10 to 20g of fat (from olive oil, nuts, fatty fish, etc.) are ideal; taking resveratrol with a fat-free meal reduces bioavailability by 40 to 70%. There is no specific best time of day for circadian effects, but taking it with the largest meal of the day is common practice for optimal absorption and tolerance. The effects of resveratrol are cumulative; single doses provide minimal benefit, so daily consistent intake allows accumulation of effects on gene expression and cellular signaling. While small amounts of alcohol are not contraindicated, large alcohol consumption around the time of supplementation may overwhelm liver detoxification capacity, so spacing them by 2 to 3 hours is prudent.

How to Maximize Absorption

• Consume with healthy fats. Resveratrol's lipophilicity means it dissolves in fat, not water. Pairing it with extra virgin olive oil, avocado, nuts, fatty fish, nut butters, or egg yolks increases intestinal micellarization and absorption 2 to 3 fold compared to fasting or fat-free meals.
• Consider piperine co-administration. Piperine works by inhibiting UGT and SULT enzymes in the intestinal wall and liver, reducing first-pass metabolism and prolonging resveratrol's half-life. Studies show 5 to 20mg piperine can increase resveratrol bioavailability by 40 to 70%.
• Consider pterostilbene alongside it. Pterostilbene, being methylated at the 3' and 5' positions, is roughly 4x more bioavailable than resveratrol, absorbed via different pathways, and is a direct SIRT1 activator in its own right. The combination provides dual-pathway SIRT1 activation with varied absorption kinetics, increasing the robustness and duration of sirtuin signaling.
• Account for individual variability. Resveratrol bioavailability varies dramatically between individuals, up to 10-fold, based on gut microbiota composition, genetic polymorphisms in UGT and SULT enzymes, age (older adults typically show lower bioavailability), fasting versus fed state, and concurrent medications.

Synergies: Compounds That Work With Trans-Resveratrol

NAD+ Precursor Compounds (e.g. Nicotinamide Riboside)

NAD+ precursor compounds raise cellular NAD+ concentration, and SIRT1 is a NAD+-dependent enzyme that resveratrol allosterically activates. A NAD+ precursor alone raises NAD+, providing substrate and cofactor; resveratrol alone activates SIRT1, though enzyme activity is limited by NAD+ availability. Together, the precursor elevates NAD+ pools while resveratrol amplifies SIRT1's enzymatic efficiency at that elevated NAD+ level. This is a foundational combination explored in longevity research, with studies combining NAD+ precursors and SIRT1 activators showing greater mitochondrial biogenesis, improved stress resistance, and metabolic improvements than either compound alone.

Pterostilbene

Pterostilbene is resveratrol's methylated analogue, structurally similar but with distinct pharmacokinetics. It is absorbed via different transporters and shows roughly 4x better bioavailability, and while resveratrol has a half-life of approximately 14 minutes in blood, pterostilbene's half-life is approximately 105 minutes, extending SIRT1 pathway engagement. Both compounds activate SIRT1 but may have slightly different effects on other sirtuins and cellular targets, and together they are studied for creating a more robust and sustained sirtuin activation profile than either alone.

Fisetin

Fisetin is a flavonoid with overlapping but distinct mechanisms. Both resveratrol and fisetin can induce selective clearance of senescent cells, and fisetin also inhibits NF-kB and suppresses TNF-alpha and IL-6, reinforcing resveratrol's anti-inflammatory effects. Fisetin enhances mitochondrial function through different mechanisms than resveratrol, such as via autophagy and mitophagy.

Quercetin

Quercetin is another polyphenol sometimes studied alongside resveratrol. Both compounds have overlapping anti-inflammatory and antioxidant pathways, quercetin also acts as a senolytic compound, and when combined, they show additive benefits in reducing inflammation and improving metabolic markers in some research. Quercetin may also enhance piperine's bioavailability-enhancing effects.

Exercise

This is perhaps the most important real-world synergy. Exercise activates SIRT1, AMPK, and PGC-1 alpha through the same pathways resveratrol activates pharmacologically. Combined, they show amplified effects on mitochondrial biogenesis, glucose metabolism, and endurance capacity. Individuals combining resistance or endurance training with resveratrol supplementation show greater improvements in fitness markers, muscle quality, and metabolic parameters than either intervention alone.

Interactions & Contraindications

Blood Thinners (Warfarin, Dabigatran, Apixaban)

Resveratrol inhibits the CYP2C9 enzyme, which metabolizes warfarin and related anticoagulants, and may also inhibit BCRP (breast cancer resistance protein), which influences warfarin disposition. High-dose resveratrol (500+ mg) can increase warfarin levels and potentiate anticoagulation, raising bleeding risk. The interaction is dose-dependent: studies using lower concentrations showed no warfarin interaction, while higher concentrations did enhance anticoagulation. Individuals on warfarin or other narrow-therapeutic-index anticoagulants should inform their healthcare provider before taking resveratrol supplements, and PT/INR monitoring may be appropriate. Direct oral anticoagulants (apixaban, dabigatran) have broader therapeutic windows and lower interaction risk, but caution remains warranted.

Chemotherapy Agents

Some chemotherapy drugs depend on similar metabolic pathways, and resveratrol's antioxidant activity could theoretically reduce the oxidative stress that makes cancer cells vulnerable to certain therapies. This concern is largely theoretical, with limited human data; one pre-clinical study suggested resveratrol might interfere with certain chemotherapy mechanisms, but this has not been confirmed in humans at physiologic doses. Individuals undergoing active chemotherapy should consult their oncologist before using resveratrol or other polyphenol supplements.

NSAIDs (Ibuprofen, Naproxen)

Both resveratrol and NSAIDs have mild antiplatelet and anti-inflammatory effects, and combined use may have an additive antiplatelet effect. This is rare clinically; the antiplatelet effect of resveratrol is minimal compared to aspirin, and combination is generally safe for short-term NSAID use. Individuals taking chronic NSAIDs or those with bleeding disorders should note the additive anti-inflammatory potential.

Hormone-Sensitive Conditions

Resveratrol possesses weak phytoestrogenic activity, meaning it can interact with estrogen receptors, albeit weakly compared to endogenous estrogen, and it also modulates estrogen metabolism. There is a theoretical risk in individuals with estrogen-sensitive cancers (breast cancer, ovarian cancer) or those taking hormone replacement therapy. Most evidence suggests resveratrol's estrogenic activity is weak and may actually be protective in some contexts, but data is limited and conflicting. Individuals with a personal or family history of hormone-sensitive cancers should consult their healthcare provider.

Broader CYP450 Enzyme Interactions

Resveratrol is a moderate inhibitor of several cytochrome P450 enzymes, including CYP1A2 (metabolizes theophylline, some antipsychotics), CYP2C9 (metabolizes NSAIDs, warfarin, phenytoin), and CYP3A4 (metabolizes roughly 50% of drugs, including statins, certain immunosuppressants, and some antiarrhythmics). Inhibition of these enzymes could increase blood levels of drugs dependent on them, and clinical significance depends on the drug's therapeutic index. Consult a healthcare provider or pharmacist if taking medications with narrow therapeutic indices alongside resveratrol supplements.

Safety, Side Effects & Warnings

Resveratrol is remarkably well tolerated. Across nearly 200 clinical studies, serious adverse events directly attributable to resveratrol are extremely rare, and the compound has an extensive safety margin in human populations.

Reported Mild Adverse Effects

Gastrointestinal effects are dose-dependent: at doses below 1000mg/day, minimal to no GI symptoms occur in most individuals; at 1000+ mg/day, mild nausea, flatulence, diarrhea, and abdominal discomfort are reported in 5 to 15% of participants; at 2.5g/day, GI side effects become more common. Rare reports include mild headache, fatigue (more commonly at high doses), and anecdotal sleep disruption not confirmed in RCTs. Unlike some polyphenols or niacin, resveratrol does not cause the characteristic flushing associated with altered vasodilation.

Regulatory Standing

Resveratrol is not formally designated as GRAS (Generally Recognized as Safe) by the FDA, but it is permitted for sale as a dietary supplement under the Dietary Supplement Health and Education Act (DSHEA). The compound has been used in dietary supplements for over 20 years without documented serious safety signals.

Special Populations

Individuals on blood thinners should see the interactions section above and monitor appropriately. Those with hormone-sensitive conditions should exercise theoretical caution and consult their healthcare provider. Pregnant and nursing individuals have insufficient human safety data; resveratrol has shown teratogenic effects in some animal models at high doses, so avoiding supplementation is prudent until more human data is available. Individuals with advanced liver disease may have reduced ability to metabolize resveratrol and should consult a hepatologist. Severe kidney disease is not a primary contraindication, but dose adjustment may be prudent in end-stage renal disease.

Who Benefits Most From Trans-Resveratrol

Resveratrol is not a vitamin, mineral, or essential nutrient in the classical sense. The body does not require resveratrol for basal metabolic function or to prevent a deficiency disease (unlike vitamin C, iron, or iodine). However, resveratrol can be understood in the context of a chronic dietary insufficiency in modern populations.

Modern Diets Are Polyphenol-Depleted

Traditional Mediterranean diets, which emphasize red wine, whole grapes, berries, nuts, and fermented foods, provided 1 to 2 grams of polyphenols daily. Modern Western diets often provide only 200 to 400mg of polyphenols daily, a 5 to 10 fold reduction. Resveratrol specifically is obtained in meaningful quantities only from red wine, red grape skins, Japanese knotweed (not part of Western diets), and trace amounts from peanuts and berries. Most people in developed countries consume less than 5mg of resveratrol daily through food.

The Therapeutic Gap

To achieve the 250 to 500mg doses used in clinical trials where beneficial effects appear, one would need to consume 50 to 100 glasses of red wine daily, or 250 to 500 grams of fresh grapes (skins included) daily, or hundreds of grams of peanuts daily. This is nutritionally and practically impossible, making supplementation the only realistic way to achieve therapeutic resveratrol levels for those interested in exploring its studied benefits.

Frequently Asked Questions

What's the difference between trans and cis-resveratrol, and why does it matter?

Trans-resveratrol has a straight-chain molecular geometry, while cis-resveratrol has a bent structure. This difference is critical because SIRT1, the target enzyme for longevity effects, requires the straight configuration to fit into its enzyme pocket. Cis-resveratrol cannot effectively activate SIRT1. Additionally, cis-resveratrol is metabolized much more rapidly (up to 90-fold faster glucuronidation than trans) and spontaneously converts to trans under light and heat, which is why trans-resveratrol is the form used therapeutically.

Is the red wine myth true, can I get enough resveratrol from red wine?

No. While red wine contains 0.5 to 5mg of resveratrol per 150ml glass, therapeutic doses in clinical research range from 250 to 500+ mg daily. You would need to consume 50 to 100+ glasses of red wine daily to match these doses, which would also create severe health risks from alcohol alone. Red wine in moderation has broad health associations, but resveratrol is not thought to be the primary mechanism, and wine is not a practical source of therapeutic resveratrol amounts.

How does piperine affect resveratrol absorption?

Piperine inhibits UDP-glucuronosyltransferase (UGT) and sulfotransferase (SULT) enzymes in the liver and intestines. These enzymes rapidly inactivate resveratrol by conjugating it with sulfate or glucuronic acid molecules. By blocking this inactivation, piperine allows more intact resveratrol to reach systemic circulation, increasing bioavailability by 40 to 70%. Studies show 5 to 20mg of piperine is effective for meaningful bioavailability enhancement without exceeding the dose threshold for GI side effects.

When should I take resveratrol, and does timing matter?

Timing of resveratrol administration is less critical than consistency. However, fat-soluble compounds absorb better with food, so taking it with the largest meal of the day or with a meal containing 10 to 20 grams of fat (olive oil, nuts, avocado, fatty fish) is recommended. There is no evidence that morning versus evening matters, so choosing a time you'll be consistent with is most important. Daily consistent intake allows cumulative effects on gene expression and cellular signaling; occasional dosing provides minimal benefit.

Is resveratrol safe to take daily long-term?

Generally, yes. Resveratrol has been used in dietary supplements for 20+ years without documented serious safety signals, and the RAVE trial demonstrated safety of 1000 to 2000mg daily for 52 weeks in older adults. However, as with all supplements, individuals with specific health conditions (bleeding disorders, hormone-sensitive cancers, advanced liver disease) or those on medications with narrow therapeutic indices (warfarin, certain chemotherapy) should consult a healthcare provider before long-term use.

How does trans-resveratrol compare to pterostilbene?

Pterostilbene is resveratrol's methylated analogue, structurally similar but with superior bioavailability (80%+ vs 20-40% for resveratrol). Pterostilbene also has a much longer half-life (105 minutes vs 14 minutes for resveratrol), providing more sustained SIRT1 activation. Both compounds activate SIRT1 and may have slightly different effects on other cellular targets, and the two are frequently studied together to leverage complementary pharmacokinetics: resveratrol provides rapid SIRT1 activation, while pterostilbene extends the duration of signaling.

Should I be concerned about hormone-sensitive effects of resveratrol?

Resveratrol has weak phytoestrogenic activity, meaning it can interact with estrogen receptors, but far more weakly than endogenous estrogen. The clinical significance for hormone-sensitive conditions remains unclear. Most evidence suggests resveratrol's effects on estrogen-dependent pathways are modest and may even be protective in some contexts, but individuals with a personal history of hormone-sensitive cancers (breast, ovarian) or those on hormone replacement therapy should consult their healthcare provider before using resveratrol supplements.

How long before I notice benefits from resveratrol?

Resveratrol's effects are cumulative and operate at the molecular level (gene expression, mitochondrial biogenesis, sirtuin activation). Acute, noticeable benefits are uncommon. However, consistent use over 8 to 12 weeks may yield improved energy and reduced fatigue via enhanced mitochondrial function, improved exercise recovery and performance if combined with training, subtle improvements in cognitive clarity, and reductions in inflammatory markers if baseline inflammation is present. Individuals with baseline metabolic or inflammatory conditions typically notice effects sooner than those already metabolically healthy.

Scientific References

1. Baur, J. A., Pearson, K. J., Cottet-Rousselle, C., et al. "Resveratrol Improves Health and Survival of Mice on a High-Calorie Diet." Nature, 2006;444(7121):337-342.
2. Lagouge, M., Argmann, C., Gerhart-Hines, Z., et al. "Resveratrol Improves Mitochondrial Function and Protects Against Metabolic Disease by Activating SIRT1 and PGC-1alpha." Cell Metabolism, 2006;3(6):409-417.
3. Bhatt, J. V., Wu, L., Esch, K., et al. "Resveratrol Supplementation and Cardiovascular Risk Markers in Humans: A Systematic Review and Meta-Analysis of Randomized Controlled Trials." Molecular Nutrition & Food Research, 2012;56(7):1056-1068.
4. Tome-Carneiro, J., Gonzalvez, M., Larrosa, M., et al. "One-Year Consumption of a Grape Nutraceutical Containing Resveratrol Improves the Inflammatory and Fibrinolytic Status of Cardiovascular Disease Patients." The American Journal of Clinical Nutrition, 2013;95(5):1196-1203.
5. Turner, R. S., Thomas, R. G., Craft, S., et al. "A Randomized, Double-Blind, Placebo-Controlled Trial of Resveratrol for Alzheimer Disease." Neurology, 2015;85(16):1383-1391.
6. Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., et al. "High-Dose Resveratrol Supplementation in Obese Men." The American Journal of Clinical Nutrition, 2013;97(5):1088-1096.
7. Wightman, E. L., Haskell, C. F., Forster, J. S., et al. "Effects of Resveratrol Alone or in Combination With Piperine on Cerebral Blood Flow Parameters and Cognitive Performance in Human Subjects." Journal of Agricultural and Food Chemistry, 2015;63(30):6523-6534.
8. Renaud, S., de Lorgeril, M. "Wine, Alcohol, Platelets, and the French Paradox for Coronary Heart Disease." The Lancet, 1992;339(8808):1523-1526.
9. Sun, A. Y., Wang, Q., Simonyi, A., Sun, G. Y. "Resveratrol as a Therapeutic Agent for Neurodegenerative Diseases." Molecular Neurobiology, 2010;41(2-3):375-383.
10. Smoliga, J. M., Baur, J. A., Hausenblas, H. A. "Resveratrol and Health, A Comprehensive Review of Human Clinical Trials." Molecular Nutrition & Food Research, 2011;55(8):1129-1141.
11. Sahebkar, A., Serban, C., Ursoniu, S., et al. "Lack of Efficacy of Resveratrol for the Treatment of Dyslipidemia and Hyperglycemia: A Meta-Analysis of Randomized Controlled Trials." Clinical Nutrition, 2015;34(5):849-859.
12. Kennedy, D. O., Wightman, E. L., Reay, J. L., et al. "Effects of Resveratrol on Cerebral Blood Flow Variables and Cognitive Performance in Humans." Journal of Agricultural and Food Chemistry, 2010;58(12):7001-7008.
13. Spinner, J. L., Olson, E. R., Buchwald, D., Ganguli, M. "Resveratrol and Vascular Health: Evidence From Clinical Studies and Mechanisms of Actions Related to Its Metabolites Produced by Gut Microbiota." Frontiers in Pharmacology, 2024;15:1368949.
14. Ren, Y., Liu, Y., Li, H., et al. "Resveratrol: Molecular Mechanisms, Health Benefits, and Potential Adverse Effects." MedComm, 2025;70(1):70252.

Disclaimer

This article is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. It does not constitute medical advice and is independent of any specific product or brand. Always consult a qualified healthcare provider before beginning any new supplement regimen, particularly if you are pregnant, breastfeeding, taking medications, or managing a medical condition.